Structure-based optimization of click-based histone deacetylase inhibitors

European Journal of Medicinal Chemistry

Volumn 46, Issue 8, 2011, Pages 3190-3200

  Hou, Jingli ^a   Feng, Congran ^a   Li, Zhonghua ^a   Fang, Qinghong ^a   Wang, Huihui ^a   Gu, Guoxian ^a   Shi, Yikang ^b   Liu, Pi ^a   Xu, Feng ^a   Yin, Zheng ^a   Shen, Jie ^a   Wang, Peng ^a  

^a NANKAI UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

Author keywords

Click chemistry; Histone deacetylase inhibitor; Hydroxamic acid; Structure based optimization

Indexed keywords

(3 AZIDO 1 PENTEN 1 YL)BENZENE; (3 AZIDO 3 CYCLOBUTYLPROP 1 EN 1 YL)BENZENE; (3 AZIDO 3 CYCLOPENTYLPROP 1 EN 1 YL)BENZENE; (3 AZIDO 4 METHYL 1 PENTEN 1 YL)BENZENE; (3 AZIDOHEPT 1 EN 1 YL)BENZENE; (3 AZIDOHEX 1 EN 1 YL)-BENZENE; 1 (3 AZIDO 4,4 DIMETHYLPENT 1 ENYL)BENZENE; 1 (3 AZIDOBUT 1 ENYL)BENZENE; 1 (3 DIPHENYL) 4 PHENYLBUT 3 EN 2 OL; 1 (3 PHENOXYPHENYL) 3 PHENYLPROP 2 EN 1 OL; 1 (NAPHTHALEN 1 YL ) 3 PHENYLPROP 2 EN 1 OL; 1 (NAPHTHALEN 2 YL ) 3 PHENYLPROP 2 EN 1 OL; 1 CYCLOBUTYL 1 PHENYLPROP 2 EN 3 OL; 1 CYCLOPENTYL 1 PHENYLPROP 2 EN 3 OL; 1 PHENYL 1 BUTEN 3 OL; 1 PHENYL 1 PENTEN 3 OL; 1 PHENYLHEPT 1 EN 3 OL; 1 PHENYLHEX 1 EN 3 OL; 1 PHENYLPENTA 1,4 DIEN 3 OL; 1,4 DIPHENYL 3 BUTEN 2 OL; 3 AZIDO 1,4 DIPHENYLBUT 1 ENE; 4 METHYL 1 PHENYL 1 PENTEN 3 OL; 4 PHENYL 1 (THIAZOL 2 YL)BUT 3 EN 2 OL; 4,4 DIMETHYL 1 PHENYLPENT 1 EN 3 OL; 5 METHYL 1 PHENYLHEX 1 EN 3 OL; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE INHIBITOR; NSC 746457; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORINOSTAT;

ARTICLE; CANCER INHIBITION; CLICK CHEMISTRY; CRYSTAL STRUCTURE; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SYNTHESIS; HYDROPHOBICITY; IC 50; MOLECULAR DOCKING;

ANTINEOPLASTIC AGENTS; BINDING SITES; CELL LINE, TUMOR; CELL PROLIFERATION; CLICK CHEMISTRY; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; HYDROXAMIC ACIDS; MODELS, MOLECULAR; NEOPLASMS; PHENYLALANINE; PROTEIN BINDING; PROTEIN STRUCTURE, SECONDARY; STRUCTURE-ACTIVITY RELATIONSHIP; TRIAZOLES;

EID: 79958289115     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2011.04.027     Document Type: Article

References (24)

1. J. Shen, R. Woodward, J.P. Kedenburg, X.W. Liu, M. Chen, L.Y. Fang, D.X. Sun, and P.G. Wang Histone deacetylase inhibitors through click chemistry J. Med. Chem. 51 2008 7417 7427
2. P.A. Marks, V.M. Richon, and R.A. Rifkind Histone deacetylase inhibitors as new cancer drugs Curr. Opin. Oncol. 13 2001 477 483 (Pubitemid 33027900)
3. P.D. Gregory, K. Wagner, and W. Hörz Histone acetylation and chromatin remodeling Exp. Cell Res. 265 2001 195 202 (Pubitemid 32980207)
4. J. Deckert, and K. Struhl Histone acetylation at promoters is differentially affected by activators and repressors Mol. Cell Biol. 8 2001 2726 2735 (Pubitemid 32244917)
5. S. Kochbin, A. Verdel, C. Lemercier, and D. Seigneurin-Berny Functional significance of histone deacetylase diversity Curr. Opin. Genet. Dev. 11 2001 162 166 (Pubitemid 32209200)
6. G.G. Gray, and T.J. Ekstrom The human histone deacetylase family Exp. Cell Res. 262 2001 75 83 (Pubitemid 32980246)
7. F.D. Urnov, and A.P. Wolffe Chromatin organisation and human disease Emerging Ther. Targets 4 2000 665 685
8. S.Y. Roth, J.M. Denu, and C.D. Allis Histone acetyltransferases Annu. Rev. Biochem. 70 2001 81 120 (Pubitemid 32662206)
9. S. Thiagalingam, K.H. Cheng, H.J. Lee, N. Mineva, A. Thiagalingam, and J.F. Ponte Histone deacetylase: unique players in shaping the epigenetic histone code Ann. N. Y. Acad. Sci. 983 2003 84 100 (Pubitemid 36399322)
10. P.A. Marks, V.M. Richon, T. Miller, and W.K. Kelly Histone deacetylase inhibitors Adv. Cancer Res. 91 2004 137 168 (Pubitemid 39140958)
11. E.A. Olsen, Y.H. Kim, T.M. Kuzel, T.R. Pacheco, F.M. Foss, S. Parker, S.R. Frankel, C. Chen, J.L. Ricker, J.M. Arduino, and M. Duvic Phase IIb multicenter trial of vorinostate in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma J. Clin. Oncol. 25 2007 3109 3115 (Pubitemid 47218059)
12. M. Duvic, R. Talpur, X. Ni, C.L. Zhang, P. Hazarika, C. Kelly, J.H. Chiao, J.F. Reilly, J.L. Ricker, V.M. Richon, and S.R. Frankel Phase 2 trial of oral vorinostate (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma Blood 109 2007 31 39 (Pubitemid 46053039)
13. R.L. Piekarz, R. Frye, M. Turner, J.J. Wright, S.L. Allen, M.H. Kirschbaum, J. Zain, H.M. Prince, J.P. Leonard, L.J. Geskin, C. Reeder, D. Joske, W.D. Figg, E.R. Gardner, S.M. Steinberg, E.S. Jaffe, M. Stetler-Stevenson, S. Lade, A.T. Fojo, and S.E. Bates Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma J. Clin. Oncol. 27 2009 5410 5417
14. D.F. Wang, O. Wiest, P. Helquist, H.Y. Lan-Hargest, and N.L. Wiech On the function of the 14 long internal cavity of histone deacetylase-like protein: implication for the design of histone deacetylase inhibitors J. Med. Chem. 47 2004 3409 3417 (Pubitemid 38746091)
15. H. Park, and S.J. Lee Homology modeling, force field design, and free energy simulation studies to optimize the activities of histone deacetylase inhibitors J. Comput. Aided Mol. Des. 18 2004 375 388 (Pubitemid 40069136)
16. S. Massa, A. Mai, G. Sbardella, M. Esposito, R. Ragno, P. Loidl, and G. Brosch 3-(4-Aroyl-1H-pyrrol-2-yl)-N-hydroxy-2-propenamides, a new class of synthetic histone deacetylase inhibitors J. Med. Chem. 44 2001 2069 2072 (Pubitemid 32861767)
17. D.F. Wang, P. Helquist, N.L. Wiech, and O. Wiest Toward selective histone deacetylase inhibitor design: homology modeling, docking studies, and molecular dynamics simulations of human class I histone deacetylases J. Med. Chem. 48 2005 6936 6947 (Pubitemid 41533115)
18. C. N. Cronin, M. T. Hilgers, M. W. Knuth, M. E. Navre, C. Sang, R. J. Skene, L. W. Tari, K. P. Wilson, D. Witemer, H. Zou, Crystallization of histone deacetylase 2, US 7507552 B1 (2009), 197pp.
19. J.C. Bressi, A.J. Jennings, R. Skene, Y.Q. Wu, R. Melkus, R.D. Jong, S. O'Connell, C.E. Grimshaw, M. Navre, and A.R. Gangloff Exploration of the HDAC2 foot pocket: synthesis and SAR of substituted N-(2-aminophenyl)benzamides Bioorg. Med. Chem. Lett. 20 2010 3142 3145
20. D.J. Dixon, S.V. Ley, and D.A. Longbottom Copper(I)-catalyzed preparation of (E)-3-iodoprop-2-enoic acid Org. Synth. 80 2003 129 132 (Pubitemid 37123739)
21. J.D. Dignam, R.M. Lebovitz, and R.G. Roeder Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei Nucleic Acids Res. 11 1983 1475 1489
22. D. Wegener, F. Wirsching, D. Riester, and A. Schwienhorst A fluorogenic histone deacetylase assay well suited for high-throughput activity screening Chem. Biol. 10 2003 61 68 (Pubitemid 36154475)
23. Grignard Reagents were purchased from Alfa Aesar, such as ethylmagnesium bromide solution 1 M in THF; tertbutylmagnesium chloride solution 1.7 M in THF; allylmagnesium chloride solution 1.7 M in THF.
24. The others were prepared according to the reference F. Owens, R. Fellmann, and F. Zimmerman Notes - the preparation of Grignard reagents under Helium and Argon J. Org. Chem. 25 1960 1808 1809